v3.25.4
Discontinued operations (Tables)
 12 Months Ended
Dec. 31, 2025
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Balance Sheet and Statement of Operation
The following table summarizes the major income and expense line items of discontinued operations, as reported in the consolidated statements of operations for the year ended December 31:
2023
Selling, general and administrative expense$1,728 
Research and development expense396 
Change in fair value of contingent consideration(a)
1,710 
Depreciation and amortization(a)
4,264 
Operating loss from discontinued operations(8,098)
Interest expense, net(a)
4,889 
Other expense(b)
61,442 
Other expense66,331 
Net loss from discontinued operations(74,429)
Loss attributable to noncontrolling interest—discontinued operations14,937 
Net loss attributable to Bioventus Inc.—discontinued operations$(59,492)
(a)Depreciation and amortization, the change in fair value of contingent consideration and interest expense represent the significant operating non-cash items of discontinued operations.
(b)Other expense includes the $60,639 loss on deconsolidation, of which $10,150 was attributable to non-refundable payments. Total investing cash outflows included these non-refundable payments and $1,356 cash on hand at disposal.